Compared with CA19-9, as the conventional tumor marker for pancreatic cancer, serum EphA2-NF could diagnose approximately 50% of early-stage pancreatic cancer cases in both the test and validation cohorts. This evidence concerns the gene EPHA2 and familial pancreatic carcinoma.